Danaher Corporation vs Msci Inc — how do they compare? Danaher Corporation trades at $220.25 (market cap $152.87B), while Msci Inc trades at $563.42 (market cap $40.38B). The key difference: Danaher Corporation is far larger — about 3.8× Msci Inc's market cap, and Msci Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Msci Inc for 82 Days on average.
| DHR | MSCI | |
|---|---|---|
Market Cap | $152.87B | $40.38B |
Volume | 5,228,698 | 414,140 |
Sector | Health | Financials |
52-Week High | $242.05 | $643.83 |
52-Week Low | $161.91 | $511.84 |
Typical Hold Time | 69 Days | 82 Days |
Enterprise Value | $175.08B | $46.54B |
Dividend Yield | 0.74% | 1.48% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
MSCI trades at $565.05, up 1.74% on the day, with a neutral technical signal and key resistance near $567. The company reported Q2 2026 earnings of $4.94 per share, slightly missing estimates, but maintains strong fundamentals with 40.73% net income margin and revenue growth to $3.13 billion in 2025. Recent news includes the completion of the First Street acquisition and upcoming Q3 2026 earnings call.
The outlook is supported by high analyst bullishness (74% buy ratings) and a consensus price target of $701.71, implying significant upside. Risks include high valuation multiples (P/E 30.37) and substantial long-term debt of $4.51 billion. Earnings growth and execution on strategic acquisitions are critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →